\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\ notable\\ only\\ for\\ bilateral\\ conjunctivitis\\ and\\ conjunctival\\ hemorrhage\\ and\\ swelling\\ \ \(0\)\
\-\ lab\\:\ \(0\)\
\-\ no\\ abnormal\\ findings\ \(3\)\
\-\ the\\ patient\\ is\\ currently\\ being\\ followed\\ by\\ hematology\\/oncology\\.\\ \\ treatment\\ plan\\ currently\\ pending\\ further\\ bone\\ marrow\\ biopsy\\ confirmation\\ of\\ current\\ diagnosis\\.\ \(0\)\
\-\ head\\ ct\\:\\ bilateral\\ lacrimal\\ gland\\ enlargement\\ with\\ homogenous\\ tissue\\ attenuation\\.\\ \\ multiple\\ lucenies\\ of\\ the\\ skull\\ bilaterally\\,\\ particularly\\ posterior\\ to\\ the\\ vertex\\ ranging\\ 5\\-9\\ mm\\ in\\ size\\.\\ \\ diffuse\\ soft\\ tissue\\ attenuation\\ noted\\ in\\ right\\ maxillary\\ sinus\\ consistent\\ with\\ sinusitis\\.\\ \\ \\ \\ \ \(0\)\
\-\ skeletal\\ survey\\:\\ left\\ upper\\ extremity\\-single\\ round\\,\\ punched\\-out\\ appearing\\ lucencies\\ in\\ the\\ region\\ of\\ the\\ radial\\ tuberosity\\ and\\ proximal\\ humerus\\;\\ pa\\-chest\\-single\\,\\ round\\,\\ punched\\ out\\ appearing\\ lucency\\ in\\ the\\ lateral\\ left\\ clavicle\\;\\ skull\\-numerous\\,\\ round\\,\\ punched\\-out\\ appearing\\ lucencies\\ over\\ the\\ parietal\\ and\\ frontal\\ bones\\.\ \(0\)\
\-\ multiple\\ myeloma\\ \\ \\ and\\ secondary\\ amyloidosis\\ and\\ history\\ of\\ sarcoidosis\ \(0\)\
\-\ multiple\\ myeloma\ \(25\)\
\-\ osteolytic\\ metastatic\\ carcinoma\ \(0\)\
\-\ hyperparathyroidism\ \(35\)\
\-\ 46\\ year\\-old\\ woman\\ with\\ history\\ of\\ sarcoidosis\\,\\ anemia\\,\\ hypertension\\,\\ and\\ carpal\\ tunnel\\ syndrome\\ with\\ complaint\\ of\\ intermittent\\ bilateral\\ conjunctival\\ inflammation\\ and\\ hemorrhage\\ for\\ one\\ year\\.\\ \\ she\\ was\\ initially\\ seen\\ by\\ opthalmology\\ who\\ diagnosed\\ and\\ treated\\ her\\ for\\ conjunctivitis\\ associated\\ with\\ bilateral\\ lacrimal\\ gland\\ enlargement\\ demonstrated\\ on\\ numerous\\ ct\\ studies\\ of\\ the\\ orbits\\.\\ \\ she\\ was\\ diagnosed\\ with\\ sarcoidosis\\ thirteen\\ years\\ prior\\ via\\ bronchoscopy\\ and\\ maintains\\ that\\ she\\ has\\ remained\\ asymptomatic\\.\\ \\ she\\ also\\ has\\ bilateral\\ upper\\ extremity\\ paresthesias\\ that\\ are\\ diffuse\\ but\\ most\\ notable\\ in\\ the\\ ulnar\\ nerve\\ distribution\\ of\\ both\\ the\\ right\\ and\\ left\\ hands\\ and\\ she\\ has\\ been\\ diagnosed\\ with\\ bilateral\\ carpal\\ tunnel\\ syndrome\\ in\\ the\\ past\\ year\\.\\ \\ she\\ presents\\ with\\ no\\ other\\ complaints\\ and\\ review\\ of\\ systems\\ is\\ negative\\ for\\ constitutional\\,\\ cardiopulmonary\\,\\ gastrointestinal\\,\\ genitourinary\\,\\ or\\ musculoskeletal\\ complaints\\.\\ \\ her\\ most\\ recent\\ head\\ ct\\ was\\ obtained\\ during\\ evaluation\\ of\\ uri\\ symptoms\\ and\\ pain\\ over\\ the\\ right\\ maxillary\\ sinus\\,\\ for\\ which\\ she\\ was\\ diagnosed\\ with\\ sinusitis\\.\ \(0\)\
\-\ this\\ is\\ a\\ case\\ of\\ a\\ 46\\ year\\-old\\ black\\ female\\ with\\ a\\ history\\ of\\ sarcoidosis\\ diagnosed\\ at\\ age\\ 32\\ years\\,\\ and\\ bilateral\\ carpal\\ tunnel\\ syndrome\\ diagnosed\\ within\\ the\\ past\\ year\\ now\\ presenting\\ with\\ mulitple\\ myeloma\\.\\ \\ multiple\\ myeloma\\ \\(mm\\)\\ is\\ a\\ monoclonal\\ b\\-cell\\ malignancy\\ consisting\\ of\\ terminally\\ differentiated\\ plasma\\ cells\\.\\ \\ in\\ the\\ united\\ states\\,\\ the\\ incidence\\ of\\ disease\\ is\\ 3\\-4\\ newly\\ diagnosed\\ cases\\ per\\ 100\\,000\\ population\\ per\\ year\\,\\ and\\ represents\\ 1\\%\\ of\\ all\\ malignancies\\.\\ \\ demographically\\,\\ patients\\ are\\ commonly\\ african\\-american\\,\\ with\\ males\\ slightly\\ outnumbering\\ females\\ by\\ 1\\.4\\-1\\.\\ \\ patients\\ are\\ typically\\ elderly\\ with\\ a\\ median\\ age\\ of\\ 65\\ years\\ at\\ diagnosis\\,\\ although\\ cases\\ in\\ much\\ younger\\ patients\\ have\\ been\\ reported\\.\ \(0\)\
\-\ the\\ patient\\'s\\ presentation\\ for\\ mm\\ is\\ unusual\\ given\\ her\\ relatively\\ young\\ age\\ \\(46\\ years\\)\\,\\ lack\\ of\\ physical\\ findings\\ and\\ history\\ \\(i\\.e\\.\\ fatigue\\,\\ bone\\,\\ recurrent\\ infections\\)\\,\\ and\\ laboratory\\ abnormalities\\ \\(i\\.e\\.\\ hypercalcemia\\,\\ elevated\\ creatinine\\,\\ elevated\\ total\\ protein\\)\\ suggestive\\ of\\ \\ mm\\.\\ \\ the\\ bilateral\\ lacrimal\\ gland\\ amyloidosis\\ is\\ a\\ \\ unusual\\ initial\\ presentation\\ for\\ mm\\.\\ \\ by\\ comparison\\,\\ lacrimal\\ gland\\ involvement\\ in\\ sarcoidosis\\ is\\ more\\ common\\ affecting\\ 55\\-61\\%\\ of\\ patients\\ at\\ sometime\\ during\\ their\\ disease\\ course\\ with\\ similar\\ findings\\ on\\ ct\\ imaging\\.\\ \\ therefore\\,\\ her\\ management\\ was\\ based\\ on\\ the\\ conclusion\\ her\\ presentation\\ was\\ a\\ manifestation\\ of\\ her\\ sarcoidosis\\ and\\ not\\ mm\\.\\ \\ the\\ lack\\ of\\ response\\ to\\ therapy\\ for\\ the\\ lacrimal\\ gland\\ enlargement\\ ultimately\\ prompted\\ a\\ biopsy\\ of\\ the\\ gland\\ six\\ months\\ from\\ the\\ time\\ she\\ sought\\ medical\\ attention\\,\\ and\\ one\\ year\\ since\\ she\\ reported\\ initially\\ having\\ symptoms\\.\\ \ \(0\)\
\-\ the\\ lacrimal\\ gland\\ biopsy\\ showed\\ an\\ inflamatory\\ cell\\ infiltrate\\,\\ with\\ nodules\\ of\\ pauci\\-cellular\\,\\ eosinophillic\\ staining\\ material\\ exhibiting\\ apple\\-green\\ birefringence\\ on\\ congo\\ red\\ staining\\.\\ \\ this\\ is\\ consistent\\ with\\ amyloidosis\\ of\\ the\\ lacrimal\\ gland\\.\\ \\ the\\ lack\\ of\\ evidence\\ of\\ granulomatous\\ disease\\ present\\ in\\ the\\ biopsy\\ specimen\\ strongly\\ suggests\\ that\\ sarcoidosis\\ is\\ not\\ the\\ etiology\\ of\\ her\\ lacrimal\\ gland\\ enlargement\\.\\ \\ \ \(0\)\
\-\ based\\ on\\ the\\ above\\ findings\\,\\ the\\ patient\\ received\\ further\\ laboratory\\ and\\ radiological\\ investigations\\ for\\ the\\ diagnosis\\ of\\ mm\\.\\ \\ \\ the\\ diagnosis\\ of\\ mm\\ is\\ based\\ on\\ the\\ demonstration\\ of\\ three\\ components\\:\\ 1\\)\\ serum\\ or\\ urine\\ monoclonal\\ protein\\ identified\\ by\\ a\\ characteristic\\ monoclonal\\ m\\ protein\\ spike\\ on\\ electrophoresis\\ of\\ urine\\ and\\ blood\\ specimens\\;\\ 2\\)\\ \\>10\\%\\ abnormal\\ plasma\\ cells\\ on\\ bone\\ marrow\\ biopsy\\;\\ and\\ 3\\)\\ end\\-organ\\ damage\\ in\\ the\\ form\\ of\\ hypercalcemia\\,\\ renal\\ insufficiency\\,\\ sequelae\\ of\\ amyloid\\ deposition\\,\\ and\\/or\\ bone\\ abnormalities\\ on\\ imaging\\.\\ \\ most\\ patients\\ will\\ demonstrate\\ symptomatic\\ sequelae\\ of\\ of\\ end\\-organ\\ damage\\.\\ \\ however\\,\\ nearly\\ 25\\%\\ of\\ patients\\ with\\ mm\\ are\\ discovered\\ through\\ incidental\\ findings\\ on\\ laboratory\\ studies\\ and\\ imaging\\.\\ indeed\\,\\ radiographs\\ provided\\ the\\ only\\ significant\\ finding\\ suggestive\\ of\\ mm\\ via\\ a\\ head\\ ct\\ that\\ was\\ obtained\\ for\\ the\\ evaluation\\ of\\ uri\\ symptoms\\ of\\ sinusitis\\ in\\ an\\ emergency\\ department\\ several\\ months\\ prior\\ to\\ the\\ lacrimal\\ gland\\ biopsy\\.\\ \\ \ \(0\)\
\-\ the\\ characteristic\\ radiological\\ feature\\ of\\ mm\\ is\\ the\\ presence\\ of\\ a\\ single\\ osteolytic\\ lucency\\ \\(plasmacytoma\\)\\,\\ or\\,\\ as\\ in\\ this\\ patient\\'s\\ case\\,\\ multiple\\ discrete\\ osteolytic\\ lucencies\\ \\(myelomatous\\)\\ that\\ are\\ subcortical\\ and\\ found\\ predominantly\\ in\\ the\\ axial\\ and\\ proximal\\ appendicular\\ skeleton\\.\\ \\ lesions\\ may\\ also\\ coalesce\\ or\\ take\\ the\\ form\\ of\\ diffuse\\ osteopenia\\.\\ \\ sclerosing\\ myeloma\\ has\\ also\\ been\\ described\\,\\ although\\ it\\ is\\ rare\\.\\ \\ the\\ osteolysis\\ of\\ mm\\ is\\ mediated\\ by\\ the\\ secretion\\ of\\ chemokine\\ factors\\ by\\ the\\ malignant\\ plasma\\ cells\\ that\\ stimulate\\ osteoclast\\ proliferation\\,\\ chemotaxis\\,\\ maturation\\,\\ and\\ activity\\.\\ \\ \ \(0\)\
\-\ plain\\ film\\ radiograph\\ skeletal\\ survey\\ is\\ the\\ preferred\\ diagnostic\\ modality\\ for\\ the\\ detection\\ of\\ bony\\ involvement\\ in\\ mm\\.\\ \\ nearly\\ 50\\%\\ of\\ the\\ density\\ of\\ bone\\ must\\ be\\ affected\\ before\\ the\\ \\"punched\\-out\\"\\ lesions\\ are\\ apparent\\,\\ however\\,\\ the\\ presence\\ of\\ bone\\ lesions\\ is\\ confirmed\\ in\\ 60\\-80\\%\\ of\\ all\\ patients\\ initially\\ surveyed\\ for\\ mm\\ with\\ radiograph\\.\\ \\ other\\ useful\\ imaging\\ studies\\ include\\ mri\\,\\ which\\ may\\ be\\ used\\ for\\ the\\ precise\\ determination\\ of\\ lesion\\ size\\ and\\ location\\ for\\ bone\\ marrow\\ biopsy\\,\\ targeted\\ radiotherapy\\,\\ and\\ for\\ characterization\\ of\\ the\\ extent\\ of\\ disease\\.\\ \\ imaging\\ via\\ ct\\ is\\ adjunctive\\ to\\ mri\\ for\\ guided\\ biopsy\\ of\\ lesions\\.\\ \\ recently\\,\\ pet\\ scanning\\ has\\ shown\\ promise\\ for\\ monitoring\\ disease\\ recurrence\\ by\\ detection\\ of\\ lesions\\ not\\ readily\\ seen\\ on\\ conventional\\ radiograph\\.\\ \\ \ \(0\)\
\-\ due\\ to\\ the\\ osteolytic\\ nature\\ of\\ mm\\,\\ nuclear\\ imaging\\ via\\ technec\\ tium\\-99m\\ \\(tc\\-99m\\)\\ bone\\ scanning\\ has\\ no\\ role\\ in\\ diagnosis\\ or\\ monitoring\\.\\ \\ the\\ sensitivity\\ of\\ tc\\-99m\\ scanning\\ is\\ dependent\\ on\\ osteoblastic\\ activity\\,\\ and\\ therefore\\,\\ underestimates\\ the\\ extent\\ of\\ disease\\.\\ \\ uptake\\ of\\ tc\\-99m\\ into\\ radiographically\\ abnormal\\ regions\\ is\\ only\\ 44\\%\\ compared\\ to\\ conventional\\ plain\\ film\\.\\ \\ this\\ uptake\\ is\\ secondary\\ to\\ osteoblastic\\ activity\\ from\\ pathological\\ fracture\\,\\ calcification\\ within\\ a\\ plasmacytoma\\,\\ or\\ amyloidosis\\ in\\ association\\ with\\ tumor\\.\\ \\ \ \(0\)\
\-\ the\\ presence\\ of\\ osteolytic\\ lesions\\ is\\ not\\ pathognomonic\\ of\\ mm\\,\\ as\\ such\\ findings\\ may\\ be\\ present\\ in\\ a\\ variety\\ of\\ conditions\\ including\\ other\\ osteolytic\\ metastases\\ \\ and\\ occasionally\\ lymphoma\\)\\ and\\ hyperparathyroidism\\ \\ furthermore\\,\\ bilateral\\ lacrimal\\ gland\\ enlargement\\ with\\ homogenous\\ soft\\ tissue\\ attenuation\\ seen\\ on\\ ct\\ is\\ more\\ suggestive\\ of\\ lacrimal\\ gland\\ sarcoidosis\\ than\\ other\\ etiologies\\.\\ \\ neoplastic\\ and\\ infectious\\ processes\\ tend\\ to\\ present\\ with\\ discrete\\ lesions\\ within\\ the\\ lacrimal\\ gland\\ and\\/or\\ are\\ likely\\ unilateral\\.\\ \\ the\\ chronicity\\ of\\ symptoms\\ also\\ would\\ argue\\ against\\ a\\ bilateral\\ infection\\,\\ as\\ such\\ a\\ condition\\ would\\ be\\ likely\\ self\\-limiting\\.\\ \\ the\\ apparent\\ overlap\\ of\\ expected\\ findings\\ in\\ sarcoidosis\\ versus\\ that\\ of\\ mm\\ likely\\ contributed\\ to\\ the\\ lag\\ between\\ initial\\ presentation\\ and\\ diagnosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lacrimal\\:\\ 0\\.30334685738694483\ \(0\)\
\-\ of\\:\\ 0\\.2708929845976016\ \(0\)\
\-\ mm\\:\\ 0\\.2590912436068604\ \(0\)\
\-\ the\\:\\ 0\\.24646381391890437\ \(0\)\
\-\ gland\\:\\ 0\\.22489749676728776\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.16235700276780665\ \(0\)\
\-\ and\\:\\ 0\\.15842203161160529\ \(0\)\
\-\ osteolytic\\:\\ 0\\.14963566362367986\ \(0\)\
\-\ is\\:\\ 0\\.12830677791861092\ \(0\)\
\-\ biopsy\\:\\ 0\\.11942336732603209\ \(0\)\
\-\ bilateral\\:\\ 0\\.11445397509734304\ \(0\)\
\-\ she\\:\\ 0\\.11409442108725107\ \(0\)\
\-\ myeloma\\:\\ 0\\.11057831862150837\ \(0\)\
\-\ for\\:\\ 0\\.10973047508438856\ \(0\)\
\-\ punched\\:\\ 0\\.10947253690173228\ \(0\)\
\-\ diagnosed\\:\\ 0\\.10798506207432433\ \(0\)\
\-\ in\\:\\ 0\\.1059563809253099\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.09392018011751689\ \(0\)\
\-\ her\\:\\ 0\\.09313287864490023\ \(0\)\
\-\ bone\\:\\ 0\\.09295923819132897\ \(0\)\
\-\ with\\:\\ 0\\.08757156469105103\ \(0\)\
\-\ lesions\\:\\ 0\\.0856147973416078\ \(0\)\
\-\ monoclonal\\:\\ 0\\.08414640134463754\ \(0\)\
\-\ patients\\:\\ 0\\.0838621878246147\ \(0\)\
\-\ on\\:\\ 0\\.08361388003608698\ \(0\)\
\-\ enlargement\\:\\ 0\\.08163387282154594\ \(0\)\
\-\ tunnel\\:\\ 0\\.07583671434673621\ \(0\)\
\-\ plasma\\:\\ 0\\.07434116477643067\ \(0\)\
\-\ findings\\:\\ 0\\.07357391940693375\ \(0\)\
\-\ by\\:\\ 0\\.07234902667854934\ \(0\)\
\-\ via\\:\\ 0\\.06962470907104439\ \(0\)\
\-\ scanning\\:\\ 0\\.06949309362585679\ \(0\)\
\-\ lucencies\\:\\ 0\\.06807347644686766\ \(0\)\
\-\ imaging\\:\\ 0\\.0671514410602059\ \(0\)\
\-\ carpal\\:\\ 0\\.06657792687656212\ \(0\)\
\-\ diagnosis\\:\\ 0\\.06623899031820098\ \(0\)\
\-\ sinusitis\\:\\ 0\\.06589893203253731\ \(0\)\
\-\ that\\:\\ 0\\.06469245604382225\ \(0\)\
\-\ protein\\:\\ 0\\.059291356012102836\ \(0\)\
\-\ or\\:\\ 0\\.05926872509520753\ \(0\)\
\-\ 46\\:\\ 0\\.058698625919208984\ \(0\)\
\-\ presentation\\:\\ 0\\.05863996759331472\ \(0\)\
\-\ has\\:\\ 0\\.05836507409891971\ \(0\)\
\-\ conjunctivitis\\:\\ 0\\.05776373715459972\ \(0\)\
\-\ ct\\:\\ 0\\.05675381049974136\ \(0\)\
\-\ are\\:\\ 0\\.05656674242886496\ \(0\)\
\-\ out\\:\\ 0\\.05599333454615377\ \(0\)\
\-\ conjunctival\\:\\ 0\\.05538595251846437\ \(0\)\
\-\ lack\\:\\ 0\\.054669286288807246\ \(0\)\
\-\ disease\\:\\ 0\\.05363648753860189\ \(0\)\
\-\ marrow\\:\\ 0\\.05309344974516335\ \(0\)\
\-\ round\\:\\ 0\\.05234876565230782\ \(0\)\
\-\ years\\:\\ 0\\.05221729664451835\ \(0\)\
\-\ uri\\:\\ 0\\.05213558199200414\ \(0\)\
\-\ multiple\\:\\ 0\\.05208232826594999\ \(0\)\
\-\ suggestive\\:\\ 0\\.05202597717822238\ \(0\)\
\-\ was\\:\\ 0\\.05195370912809049\ \(0\)\
\-\ appearing\\:\\ 0\\.05105145107682504\ \(0\)\
\-\ plasmacytoma\\:\\ 0\\.050557809564490803\ \(0\)\
\-\ initially\\:\\ 0\\.05010125690943697\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.04987855454122662\ \(0\)\
\-\ staining\\:\\ 0\\.04956077651762045\ \(0\)\
\-\ cells\\:\\ 0\\.04922540972672895\ \(0\)\
\-\ single\\:\\ 0\\.04912673080803963\ \(0\)\
\-\ attenuation\\:\\ 0\\.04888377150170402\ \(0\)\
\-\ to\\:\\ 0\\.04791621492702237\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.04764980991421394\ \(0\)\
\-\ activity\\:\\ 0\\.0469060483889387\ \(0\)\
\-\ studies\\:\\ 0\\.0468658329603831\ \(0\)\
\-\ symptoms\\:\\ 0\\.04660843467154788\ \(0\)\
\-\ survey\\:\\ 0\\.04653330781388688\ \(0\)\
\-\ laboratory\\:\\ 0\\.04639418496374008\ \(0\)\
\-\ based\\:\\ 0\\.046279312317567566\ \(0\)\
\-\ year\\:\\ 0\\.04594162246415325\ \(0\)\
\-\ presence\\:\\ 0\\.04590469596377145\ \(0\)\
\-\ homogenous\\:\\ 0\\.04520662348872066\ \(0\)\
\-\ sequelae\\:\\ 0\\.04520662348872066\ \(0\)\
\-\ detection\\:\\ 0\\.04438528458437475\ \(0\)\
\-\ other\\:\\ 0\\.04423796483351928\ \(0\)\
\-\ radiological\\:\\ 0\\.04423132744860334\ \(0\)\
\-\ discrete\\:\\ 0\\.044080480771758926\ \(0\)\
\-\ conventional\\:\\ 0\\.0435058391101533\ \(0\)\
\-\ notable\\:\\ 0\\.04259572970558103\ \(0\)\
\-\ nearly\\:\\ 0\\.04247431798096825\ \(0\)\
\-\ monitoring\\:\\ 0\\.04247431798096825\ \(0\)\
\-\ maxillary\\:\\ 0\\.04223726135486263\ \(0\)\
\-\ radiograph\\:\\ 0\\.04161183977549463\ \(0\)\
\-\ damage\\:\\ 0\\.04146224634583937\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.04057112509668793\ \(0\)\
\-\ age\\:\\ 0\\.040110013945669626\ \(0\)\
\-\ also\\:\\ 0\\.040068606838181725\ \(0\)\
\-\ diffuse\\:\\ 0\\.040066178332688315\ \(0\)\
\-\ only\\:\\ 0\\.03991409084781439\ \(0\)\
\-\ extent\\:\\ 0\\.03898003124450583\ \(0\)\
\-\ skeletal\\:\\ 0\\.038612141243898515\ \(0\)\
\-\ syndrome\\:\\ 0\\.03851607441769903\ \(0\)\
\-\ abnormal\\:\\ 0\\.03838352867170699\ \(0\)\
\-\ unusual\\:\\ 0\\.03819334046055259\ \(0\)\
\-\ likely\\:\\ 0\\.038178360847929096\ \(0\)\
\-\ urine\\:\\ 0\\.038125768446925265\ \(0\)\
\-\ head\\:\\ 0\\.038104676471503875\ \(0\)\
\-\ therefore\\:\\ 0\\.03754365639295436\ \(0\)\
\-\ form\\:\\ 0\\.03723885258033853\ \(0\)\
\-\ been\\:\\ 0\\.03722233183549143\ \(0\)\
\-\ lucency\\:\\ 0\\.036664210918732905\ \(0\)\
\-\ numerous\\:\\ 0\\.03597774521741314\ \(0\)\
\-\ apparent\\:\\ 0\\.03563268978954785\ \(0\)\
\-\ per\\:\\ 0\\.03534911178835988\ \(0\)\
\-\ complaints\\:\\ 0\\.03507591095116573\ \(0\)\
\-\ skull\\:\\ 0\\.034557784769208774\ \(0\)\
\-\ be\\:\\ 0\\.03455616984354808\ \(0\)\
\-\ characteristic\\:\\ 0\\.03443368235752318\ \(0\)\
\-\ lucenies\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ terminally\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ demographically\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ outnumbering\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ congo\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ myelomatous\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ chemokine\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ chemotaxis\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ surveyed\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ technec\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ underestimates\\:\\ 0\\.03405736051054555\ \(0\)\
\-\ not\\:\\ 0\\.03362903195627505\ \(0\)\
\-\ tissue\\:\\ 0\\.03351461844282438\ \(0\)\
\-\ most\\:\\ 0\\.03324966020897997\ \(0\)\
\-\ present\\:\\ 0\\.03278341245716298\ \(0\)\
\-\ uptake\\:\\ 0\\.03275115387202642\ \(0\)\
\-\ currently\\:\\ 0\\.032718476985971974\ \(0\)\
\-\ history\\:\\ 0\\.03254562106260144\ \(0\)\
\-\ thirteen\\:\\ 0\\.032543626158678764\ \(0\)\
\-\ sometime\\:\\ 0\\.032543626158678764\ \(0\)\
\-\ birefringence\\:\\ 0\\.032543626158678764\ \(0\)\
\-\ argue\\:\\ 0\\.032543626158678764\ \(0\)\
\-\ may\\:\\ 0\\.03215085294794584\ \(0\)\
\-\ film\\:\\ 0\\.0318281709184957\ \(0\)\
\-\ opthalmology\\:\\ 0\\.031469614543922705\ \(0\)\
\-\ eosinophillic\\:\\ 0\\.031469614543922705\ \(0\)\
\-\ abnormalities\\:\\ 0\\.03085287487837838\ \(0\)\
\-\ involvement\\:\\ 0\\.03082752118153464\ \(0\)\
\-\ sinus\\:\\ 0\\.03077707060752656\ \(0\)\
\-\ extremity\\:\\ 0\\.03067718073585393\ \(0\)\
\-\ reported\\:\\ 0\\.03067718073585393\ \(0\)\
\-\ mulitple\\:\\ 0\\.030636546414835358\ \(0\)\
\-\ osteoclast\\:\\ 0\\.030636546414835358\ \(0\)\
\-\ would\\:\\ 0\\.03015046741316442\ \(0\)\
\-\ obtained\\:\\ 0\\.030127386539928334\ \(0\)\
\-\ seen\\:\\ 0\\.03007832435740338\ \(0\)\
\-\ promise\\:\\ 0\\.02995588019205592\ \(0\)\
\-\ within\\:\\ 0\\.029425205907289993\ \(0\)\
\-\ spike\\:\\ 0\\.029380385100735037\ \(0\)\
\-\ electrophoresis\\:\\ 0\\.029380385100735037\ \(0\)\
\-\ targeted\\:\\ 0\\.029380385100735037\ \(0\)\
\-\ this\\:\\ 0\\.029271117721167826\ \(0\)\
\-\ elevated\\:\\ 0\\.029035891943359267\ \(0\)\
\-\ although\\:\\ 0\\.028996175591491962\ \(0\)\
\-\ maintains\\:\\ 0\\.02888186857729986\ \(0\)\
\-\ maturation\\:\\ 0\\.02888186857729986\ \(0\)\
\-\ adjunctive\\:\\ 0\\.02888186857729986\ \(0\)\
\-\ size\\:\\ 0\\.028839389640931554\ \(0\)\
\-\ cases\\:\\ 0\\.028647926418530603\ \(0\)\
\-\ initial\\:\\ 0\\.028572694985651084\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.02851676471254873\ \(0\)\
\-\ inflamatory\\:\\ 0\\.028442145840189132\ \(0\)\
\-\ exhibiting\\:\\ 0\\.028442145840189132\ \(0\)\
\-\ investigations\\:\\ 0\\.028442145840189132\ \(0\)\
\-\ mediated\\:\\ 0\\.028442145840189132\ \(0\)\
\-\ plain\\:\\ 0\\.02810134174267196\ \(0\)\
\-\ coalesce\\:\\ 0\\.028048800448212508\ \(0\)\
\-\ stimulate\\:\\ 0\\.028048800448212508\ \(0\)\
\-\ overlap\\:\\ 0\\.028048800448212508\ \(0\)\
\-\ further\\:\\ 0\\.02774122651699642\ \(0\)\
\-\ past\\:\\ 0\\.027724503874964352\ \(0\)\
\-\ patient\\:\\ 0\\.027706420836898085\ \(0\)\
\-\ chronicity\\:\\ 0\\.027692976259232185\ \(0\)\
\-\ such\\:\\ 0\\.027397683367128393\ \(0\)\
\-\ indeed\\:\\ 0\\.02736813422543307\ \(0\)\
\-\ secretion\\:\\ 0\\.0270693085218178\ \(0\)\
\-\ precise\\:\\ 0\\.0270693085218178\ \(0\)\
\-\ determination\\:\\ 0\\.0270693085218178\ \(0\)\
\-\ lag\\:\\ 0\\.0270693085218178\ \(0\)\
\-\ during\\:\\ 0\\.026978010531550186\ \(0\)\
\-\ characterization\\:\\ 0\\.02679263913411219\ \(0\)\
\-\ proximal\\:\\ 0\\.026609393898542923\ \(0\)\
\-\ conclusion\\:\\ 0\\.026535066096345723\ \(0\)\
\-\ sought\\:\\ 0\\.02629412261067701\ \(0\)\
\-\ osteolysis\\:\\ 0\\.02606779099600207\ \(0\)\
\-\ evaluation\\:\\ 0\\.02597531162639891\ \(0\)\
\-\ specimens\\:\\ 0\\.025854399873566282\ \(0\)\
\-\ contributed\\:\\ 0\\.025854399873566282\ \(0\)\
\-\ as\\:\\ 0\\.02566639380049456\ \(0\)\
\-\ vertex\\:\\ 0\\.02546105448158966\ \(0\)\
\-\ ranging\\:\\ 0\\.02546105448158966\ \(0\)\
\-\ all\\:\\ 0\\.025354315797166904\ \(0\)\
\-\ tuberosity\\:\\ 0\\.025278904782245402\ \(0\)\
\-\ secondary\\:\\ 0\\.025245664067654012\ \(0\)\
\-\ however\\:\\ 0\\.02520979535233656\ \(0\)\
\-\ readily\\:\\ 0\\.02510523029260934\ \(0\)\
\-\ cardiopulmonary\\:\\ 0\\.02493927727061331\ \(0\)\
\-\ genitourinary\\:\\ 0\\.02493927727061331\ \(0\)\
\-\ appendicular\\:\\ 0\\.02493927727061331\ \(0\)\
\-\ months\\:\\ 0\\.02479229587143902\ \(0\)\
\-\ newly\\:\\ 0\\.024627986352502313\ \(0\)\
\-\ paresthesias\\:\\ 0\\.024481562555194954\ \(0\)\
\-\ one\\:\\ 0\\.02438622036415674\ \(0\)\
\-\ cell\\:\\ 0\\.0243648870452264\ \(0\)\
\-\ constitutional\\:\\ 0\\.0243406655216995\ \(0\)\
\-\ feature\\:\\ 0\\.0243406655216995\ \(0\)\
\-\ manifestation\\:\\ 0\\.02420489316748934\ \(0\)\
\-\ demonstration\\:\\ 0\\.02420489316748934\ \(0\)\
\-\ at\\:\\ 0\\.02413160424862621\ \(0\)\
\-\ orbits\\:\\ 0\\.024073885751096577\ \(0\)\
\-\ amyloid\\:\\ 0\\.024073885751096577\ \(0\)\
\-\ malignancies\\:\\ 0\\.023947320129722872\ \(0\)\
\-\ prior\\:\\ 0\\.02383059295836859\ \(0\)\
\-\ consisting\\:\\ 0\\.023706376644054162\ \(0\)\
\-\ over\\:\\ 0\\.02368331685139197\ \(0\)\
\-\ prompted\\:\\ 0\\.023480045029379223\ \(0\)\
\-\ more\\:\\ 0\\.023387852197650057\ \(0\)\
\-\ bronchoscopy\\:\\ 0\\.02326665390694344\ \(0\)\
\-\ united\\:\\ 0\\.02326665390694344\ \(0\)\
\-\ attention\\:\\ 0\\.02326665390694344\ \(0\)\
\-\ plan\\:\\ 0\\.023164364541952268\ \(0\)\
\-\ skeleton\\:\\ 0\\.023164364541952268\ \(0\)\
\-\ furthermore\\:\\ 0\\.023164364541952268\ \(0\)\
\-\ physical\\:\\ 0\\.023094645188534504\ \(0\)\
\-\ consistent\\:\\ 0\\.023094645188534504\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.02306480322112569\ \(0\)\
\-\ clavicle\\:\\ 0\\.022967828203328166\ \(0\)\
\-\ subcortical\\:\\ 0\\.022967828203328166\ \(0\)\
\-\ proliferation\\:\\ 0\\.022873308514966814\ \(0\)\
\-\ confirmation\\:\\ 0\\.022781122886245803\ \(0\)\
\-\ upper\\:\\ 0\\.02276078610732426\ \(0\)\
\-\ specimen\\:\\ 0\\.022691158815622555\ \(0\)\
\-\ soft\\:\\ 0\\.02267535432238532\ \(0\)\
\-\ infiltrate\\:\\ 0\\.02260331174436033\ \(0\)\
\-\ preferred\\:\\ 0\\.02260331174436033\ \(0\)\
\-\ variety\\:\\ 0\\.02251748432598649\ \(0\)\
\-\ elderly\\:\\ 0\\.022433585777856088\ \(0\)\
\-\ sclerosing\\:\\ 0\\.022433585777856088\ \(0\)\
\-\ role\\:\\ 0\\.02235153130399046\ \(0\)\
\-\ younger\\:\\ 0\\.022271241579991358\ \(0\)\
\-\ ultimately\\:\\ 0\\.022271241579991358\ \(0\)\
\-\ pathological\\:\\ 0\\.022192642292187374\ \(0\)\
\-\ osteopenia\\:\\ 0\\.02211566372430167\ \(0\)\
\-\ median\\:\\ 0\\.022040240385879463\ \(0\)\
\-\ males\\:\\ 0\\.021966310677512434\ \(0\)\
\-\ mri\\:\\ 0\\.021863223457445864\ \(0\)\
\-\ black\\:\\ 0\\.021822703423735972\ \(0\)\
\-\ left\\:\\ 0\\.021793859191353897\ \(0\)\
\-\ tend\\:\\ 0\\.02175291955507665\ \(0\)\
\-\ creatinine\\:\\ 0\\.02168441619689914\ \(0\)\
\-\ take\\:\\ 0\\.021617147200866493\ \(0\)\
\-\ sensitivity\\:\\ 0\\.021617147200866493\ \(0\)\
\-\ against\\:\\ 0\\.021551068869258908\ \(0\)\
\-\ deposition\\:\\ 0\\.02148613978447373\ \(0\)\
\-\ females\\:\\ 0\\.021422320653100367\ \(0\)\
\-\ affecting\\:\\ 0\\.021422320653100367\ \(0\)\
\-\ strongly\\:\\ 0\\.021422320653100367\ \(0\)\
\-\ case\\:\\ 0\\.021398021759076895\ \(0\)\
\-\ etiologies\\:\\ 0\\.021359574163100026\ \(0\)\
\-\ radiographically\\:\\ 0\\.021237158990484124\ \(0\)\
\-\ right\\:\\ 0\\.021181776858575932\ \(0\)\
\-\ remained\\:\\ 0\\.021060748459484756\ \(0\)\
\-\ modality\\:\\ 0\\.021060748459484756\ \(0\)\
\-\ gastrointestinal\\:\\ 0\\.021003749974119704\ \(0\)\
\-\ pathognomonic\\:\\ 0\\.020947608641386842\ \(0\)\
\-\ processes\\:\\ 0\\.020947608641386842\ \(0\)\
\-\ guided\\:\\ 0\\.020892299062756376\ \(0\)\
\-\ no\\:\\ 0\\.02077590706549138\ \(0\)\
\-\ fatigue\\:\\ 0\\.020627412940823587\ \(0\)\
\-\ systems\\:\\ 0\\.020576618575329417\ \(0\)\
\-\ insufficiency\\:\\ 0\\.020526506034012678\ \(0\)\
\-\ dependent\\:\\ 0\\.020526506034012678\ \(0\)\
\-\ occasionally\\:\\ 0\\.02042825488279882\ \(0\)\
\-\ differentiated\\:\\ 0\\.020332523271598346\ \(0\)\
\-\ useful\\:\\ 0\\.020332523271598346\ \(0\)\
\-\ comparison\\:\\ 0\\.020285562548343964\ \(0\)\
\-\ ulnar\\:\\ 0\\.020239185203209865\ \(0\)\
\-\ hands\\:\\ 0\\.020193376919622957\ \(0\)\
\-\ musculoskeletal\\:\\ 0\\.020193376919622957\ \(0\)\
\-\ population\\:\\ 0\\.020148123901638785\ \(0\)\
\-\ nuclear\\:\\ 0\\.020148123901638785\ \(0\)\
\-\ particularly\\:\\ 0\\.020103412848999705\ \(0\)\
\-\ humerus\\:\\ 0\\.020103412848999705\ \(0\)\
\-\ red\\:\\ 0\\.020059230933669025\ \(0\)\
\-\ pet\\:\\ 0\\.019723424638617336\ \(0\)\
\-\ neoplastic\\:\\ 0\\.01968349561336851\ \(0\)\
\-\ response\\:\\ 0\\.019643989125415495\ \(0\)\
\-\ suggests\\:\\ 0\\.019643989125415495\ \(0\)\
\-\ anemia\\:\\ 0\\.019566208639736328\ \(0\)\
\-\ unilateral\\:\\ 0\\.019490015622252915\ \(0\)\
\-\ conditions\\:\\ 0\\.019452494419256616\ \(0\)\
\-\ discovered\\:\\ 0\\.019415346567755513\ \(0\)\
\-\ which\\:\\ 0\\.019367245213472262\ \(0\)\
\-\ components\\:\\ 0\\.019342141707128484\ \(0\)\
\-\ lab\\:\\ 0\\.019234957457113126\ \(0\)\
\-\ expected\\:\\ 0\\.01919990247398775\ \(0\)\
\-\ association\\:\\ 0\\.019165173588453804\ \(0\)\
\-\ six\\:\\ 0\\.019130764789366927\ \(0\)\
\-\ serum\\:\\ 0\\.019096670230276294\ \(0\)\
\-\ represents\\:\\ 0\\.019029401234243647\ \(0\)\
\-\ granulomatous\\:\\ 0\\.01893071720828026\ \(0\)\
\-\ 44\\:\\ 0\\.01883457468647752\ \(0\)\
\-\ versus\\:\\ 0\\.01883457468647752\ \(0\)\
\-\ infections\\:\\ 0\\.018803069619568707\ \(0\)\
\-\ nature\\:\\ 0\\.018803069619568707\ \(0\)\
\-\ states\\:\\ 0\\.01871011888616767\ \(0\)\
\-\ current\\:\\ 0\\.018649413023861278\ \(0\)\
\-\ predominantly\\:\\ 0\\.018649413023861278\ \(0\)\
\-\ recently\\:\\ 0\\.018589678497132923\ \(0\)\
\-\ received\\:\\ 0\\.01853088471080847\ \(0\)\
\-\ complaint\\:\\ 0\\.0184443944733875\ \(0\)\
\-\ much\\:\\ 0\\.0184443944733875\ \(0\)\
\-\ having\\:\\ 0\\.018359862674764\ \(0\)\
\-\ incidence\\:\\ 0\\.018332105459366452\ \(0\)\
\-\ radial\\:\\ 0\\.01827720258352773\ \(0\)\
\-\ regions\\:\\ 0\\.01827720258352773\ \(0\)\
\-\ 32\\:\\ 0\\.018250050985500824\ \(0\)\
\-\ must\\:\\ 0\\.018250050985500824\ \(0\)\
\-\ 65\\:\\ 0\\.018223095429602414\ \(0\)\
\-\ distribution\\:\\ 0\\.018065325688763532\ \(0\)\
\-\ department\\:\\ 0\\.018014183405812036\ \(0\)\
\-\ factors\\:\\ 0\\.018014183405812036\ \(0\)\
\-\ material\\:\\ 0\\.017938760067389828\ \(0\)\
\-\ their\\:\\ 0\\.01767455589417994\ \(0\)\
\-\ recurrence\\:\\ 0\\.01758293587840951\ \(0\)\
\-\ young\\:\\ 0\\.017560377935015935\ \(0\)\
\-\ review\\:\\ 0\\.017537955475582866\ \(0\)\
\-\ pending\\:\\ 0\\.017515666882376858\ \(0\)\
\-\ affected\\:\\ 0\\.017515666882376858\ \(0\)\
\-\ provided\\:\\ 0\\.017471484967046178\ \(0\)\
\-\ total\\:\\ 0\\.017449588550769272\ \(0\)\
\-\ intermittent\\:\\ 0\\.017406177267761096\ \(0\)\
\-\ relatively\\:\\ 0\\.017341992392740795\ \(0\)\
\-\ described\\:\\ 0\\.017278892384604387\ \(0\)\
\-\ before\\:\\ 0\\.01721684117876159\ \(0\)\
\-\ compared\\:\\ 0\\.01721684117876159\ \(0\)\
\-\ metastases\\:\\ 0\\.01721684117876159\ \(0\)\
\-\ parietal\\:\\ 0\\.01719638453430088\ \(0\)\
\-\ etiology\\:\\ 0\\.017155804479619223\ \(0\)\
\-\ bones\\:\\ 0\\.01713567867199449\ \(0\)\
\-\ infectious\\:\\ 0\\.01713567867199449\ \(0\)\
\-\ inflammation\\:\\ 0\\.017115660778065856\ \(0\)\
\-\ recurrent\\:\\ 0\\.017075944145266135\ \(0\)\
\-\ condition\\:\\ 0\\.01701715035894168\ \(0\)\
\-\ nodules\\:\\ 0\\.016921172623979828\ \(0\)\
\-\ from\\:\\ 0\\.016915945474238872\ \(0\)\
\-\ presenting\\:\\ 0\\.01668259875328951\ \(0\)\
\-\ slightly\\:\\ 0\\.016612156507364903\ \(0\)\
\-\ shown\\:\\ 0\\.016508924263653444\ \(0\)\
\-\ bony\\:\\ 0\\.016408469908909654\ \(0\)\
\-\ symptomatic\\:\\ 0\\.01637557693601321\ \(0\)\
\-\ hypertension\\:\\ 0\\.016294590500568005\ \(0\)\
\-\ an\\:\\ 0\\.0162872388576189\ \(0\)\
\-\ similar\\:\\ 0\\.01623104295310871\ \(0\)\
\-\ diagnostic\\:\\ 0\\.01623104295310871\ \(0\)\
\-\ rare\\:\\ 0\\.01607675123239794\ \(0\)\
\-\ malignancy\\:\\ 0\\.015943138744185622\ \(0\)\
\-\ used\\:\\ 0\\.015943138744185622\ \(0\)\
\-\ emergency\\:\\ 0\\.015800081844692327\ \(0\)\
\-\ incidental\\:\\ 0\\.015786073091770738\ \(0\)\
\-\ commonly\\:\\ 0\\.015758212303714377\ \(0\)\
\-\ course\\:\\ 0\\.0157305578937602\ \(0\)\
\-\ management\\:\\ 0\\.0157305578937602\ \(0\)\
\-\ confirmed\\:\\ 0\\.015703106826894804\ \(0\)\
\-\ since\\:\\ 0\\.01542643743918919\ \(0\)\
\-\ above\\:\\ 0\\.015363479315262708\ \(0\)\
\-\ including\\:\\ 0\\.015240661388638848\ \(0\)\
\-\ calcification\\:\\ 0\\.015204590303459626\ \(0\)\
\-\ nerve\\:\\ 0\\.015192643642791126\ \(0\)\
\-\ malignant\\:\\ 0\\.015180735089557907\ \(0\)\
\-\ identified\\:\\ 0\\.015098422155498113\ \(0\)\
\-\ 25\\:\\ 0\\.015086809927557095\ \(0\)\
\-\ typically\\:\\ 0\\.014950209508960017\ \(0\)\
\-\ 50\\:\\ 0\\.014872774739170754\ \(0\)\
\-\ being\\:\\ 0\\.014840073844491788\ \(0\)\
\-\ location\\:\\ 0\\.014829236889790627\ \(0\)\
\-\ given\\:\\ 0\\.014649664565953034\ \(0\)\
\-\ now\\:\\ 0\\.014618852878490544\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.014498087795745981\ \(0\)\
\-\ recent\\:\\ 0\\.014419694820465777\ \(0\)\
\-\ followed\\:\\ 0\\.014381107104600308\ \(0\)\
\-\ swelling\\:\\ 0\\.014333426657356978\ \(0\)\
\-\ three\\:\\ 0\\.014295715950120991\ \(0\)\
\-\ bilaterally\\:\\ 0\\.014203072777643893\ \(0\)\
\-\ showed\\:\\ 0\\.01418481685728991\ \(0\)\
\-\ density\\:\\ 0\\.014121615111112781\ \(0\)\
\-\ finding\\:\\ 0\\.013998333636538442\ \(0\)\
\-\ several\\:\\ 0\\.013972437614050759\ \(0\)\
\-\ between\\:\\ 0\\.013837279748900195\ \(0\)\
\-\ radiographs\\:\\ 0\\.013812473489706588\ \(0\)\
\-\ found\\:\\ 0\\.0137796528099905\ \(0\)\
\-\ frontal\\:\\ 0\\.013706844533945156\ \(0\)\
\-\ will\\:\\ 0\\.013706844533945156\ \(0\)\
\-\ medical\\:\\ 0\\.013534626952921971\ \(0\)\
\-\ treated\\:\\ 0\\.013261784657579313\ \(0\)\
\-\ renal\\:\\ 0\\.013261784657579313\ \(0\)\
\-\ negative\\:\\ 0\\.0131843707415183\ \(0\)\
\-\ demonstrated\\:\\ 0\\.013088110167943248\ \(0\)\
\-\ infection\\:\\ 0\\.012864175040955047\ \(0\)\
\-\ region\\:\\ 0\\.012738461874950528\ \(0\)\
\-\ carcinoma\\:\\ 0\\.012738461874950528\ \(0\)\
\-\ lymphoma\\:\\ 0\\.012683243194589498\ \(0\)\
\-\ through\\:\\ 0\\.012677157898583452\ \(0\)\
\-\ include\\:\\ 0\\.012671082505423122\ \(0\)\
\-\ time\\:\\ 0\\.012622832033827006\ \(0\)\
\-\ 10\\:\\ 0\\.01245297290300347\ \(0\)\
\-\ blood\\:\\ 0\\.012368056544541484\ \(0\)\
\-\ axial\\:\\ 0\\.012301487263302963\ \(0\)\
\-\ significant\\:\\ 0\\.012295993033800481\ \(0\)\
\-\ due\\:\\ 0\\.01224149092316778\ \(0\)\
\-\ therapy\\:\\ 0\\.012236084219437674\ \(0\)\
\-\ fracture\\:\\ 0\\.012103400451358694\ \(0\)\
\-\ evidence\\:\\ 0\\.01208779069367755\ \(0\)\
\-\ common\\:\\ 0\\.012077420330695119\ \(0\)\
\-\ than\\:\\ 0\\.012072245931705831\ \(0\)\
\-\ who\\:\\ 0\\.012046480969036107\ \(0\)\
\-\ both\\:\\ 0\\.01187584218043052\ \(0\)\
\-\ metastatic\\:\\ 0\\.011679934845948077\ \(0\)\
\-\ into\\:\\ 0\\.011320726719937406\ \(0\)\
\-\ noted\\:\\ 0\\.011291247381304477\ \(0\)\
\-\ associated\\:\\ 0\\.01122472752308374\ \(0\)\
\-\ tumor\\:\\ 0\\.011139181070149214\ \(0\)\
\-\ woman\\:\\ 0\\.011091163324301493\ \(0\)\
\-\ demonstrate\\:\\ 0\\.011071336786608975\ \(0\)\
\-\ posterior\\:\\ 0\\.011012481207094364\ \(0\)\
\-\ it\\:\\ 0\\.010901259299152245\ \(0\)\
\-\ exam\\:\\ 0\\.010720549371624186\ \(0\)\
\-\ have\\:\\ 0\\.010638651428157233\ \(0\)\
\-\ lateral\\:\\ 0\\.010568867559497909\ \(0\)\
\-\ but\\:\\ 0\\.010531035258774408\ \(0\)\
\-\ female\\:\\ 0\\.010276429074332199\ \(0\)\
\-\ presents\\:\\ 0\\.010244601701064261\ \(0\)\
\-\ lesion\\:\\ 0\\.01020990216017398\ \(0\)\
\-\ treatment\\:\\ 0\\.010144540012340077\ \(0\)\
\-\ pain\\:\\ 0\\.007620586578950282\ \(0\)\
